ASX Announcement

05/03/2021

emyria
myriad data.
individual care.

Results of General Meeting

Perth, Australia; 5 March 2021: **Emyria Limited** (ASX:EMD, "Emyria" or the "Company") advises that a General Meeting of shareholders was held today, 5th March 2021.

All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Ratification of prior issue of Placement Shares	97,344,757	110,000	258,607
2	Ratification of prior issue of Placement Options	97,344,757	120,000	258,607
3	Ratification of prior issue of Lead Manager Options to Sixty Two Capital Pty Ltd	97,073,394	110,000	529,970
4	Ratification of prior issue of Consultant Options to Professor Bruce Robinson	97,095,775	0	617,589

emyria

Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Ratification of prior issue of Placement Shares	96,556,223	110,000	237,935	258,607
2	Ratification of prior issue of Placement Options	96,546,223	120,000	237,935	258,607
3	Ratification of prior issue of Lead Manager Options to Sixty Two Capital Pty Ltd	96,284,860	110,000	237,935	529,970
4	Ratification of prior issue of Consultant Options to Professor Bruce Robinson	96,307,241	0	237,935	617,589

Release authorised by:

Simon Robertson
Company Secretary

For further information:

Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com

Lexi O'Halloran
Media/Investor Relations
+61 (0) 404 577 076
lexi@janemorganmanagement.com.au

Andrew Williams
Media Relations
+61 (0) 412 614 125
andreww@profilemedia.com.au

About Emyria (www.emyria.com)

Emyria Limited is a data-backed, drug development company. **Emyria's Treatments** target unmet needs and are focused on obtaining approval from major global regulators. Emyria's drug development programs are informed by insights generated from extensive analysis of **Emyria Data** - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria's independent clinical services (**Emerald Clinics** - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.